Champions Oncology (CSBR) Q4 2026 earnings summary

Executive summary

• Achieved record annual revenue of $59.4 million for fiscal 2026, with positive Adjusted EBITDA in all four quarters for the first time since fiscal 2022.

• Continued strategic investments in data, Corellia, and the Translational Oncology Solutions (TOS) business, particularly in the radioligand platform and commercial expansion.

• Fiscal 2026 was characterized as an investment year, positioning for future growth and profitability.

Financial highlights

• Full-year revenue reached a record $59.4 million, up 12% year-over-year; Q4 revenue was $13.8 million, also up 12% from the prior year quarter.

• Adjusted EBITDA for the year was $1.6 million, with Q4 Adjusted EBITDA at $158,000.

• Fiscal year adjusted EBITDA was down from $7.1 million in the prior year, reflecting the absence of a $4.5 million non-recurring data license transaction.

• Q4 gross margin improved to 51% from 41% in the prior year quarter; full-year gross margin was 48%.

• Ended the year with $4.9 million in cash and no debt.

Outlook and guidance

• Services growth expected to moderate to a more normalized pace in the near term after a strong year.

• Revenue from the data business anticipated to remain volatile due to timing and size of transactions, but long-term opportunity seen as strong, especially as AI becomes more central to drug discovery.

• Fiscal 2027 budget assumes Corellia is funded for the full year, with potential for redeployment of investment if external funding is secured.

• Focus remains on disciplined cost management, executing the operating plan, and maintaining financial discipline.